We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $4.94B
1-Year Est. Return 244.43%
This Fund
S&P 500
This Quarter Est. Return
+34.74%
1 Year Est. Return
+244.43%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.94B
AUM Growth
+$1.33B
Cap. Flow
+$314M
Cap. Flow %
6.35%
Top 10 Hldgs %
44.63%
Holding
126
New
26
Increased
32
Reduced
21
Closed
9

Top Buys

Rank Stock Value
1
PBLS
Parabilis Medicines Inc
PBLS
+$82.7M
2
ABVX
Abivax
ABVX
+$65.2M
3
COAG
Hemab Therapeutics
COAG
+$57.6M
4
RLAY icon
Relay Therapeutics
RLAY
+$53M
5
KLRA
Kailera Therapeutics
KLRA
+$48.7M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$60.4M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$42.9M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$41.8M
4
RVMD icon
Revolution Medicines
RVMD
+$30.8M
5
KYMR icon
Kymera Therapeutics
KYMR
+$21.6M

Sector Composition

Rank Sector Weight
1 Healthcare 92.94%
2 Technology 3.57%
3 Communication Services 1.85%
4 Financials 0.87%
5 Consumer Discretionary 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FPS
126
Forgent Power Solutions
FPS
$10.2B
– –
-100,000
Closed -$2.93M
2 3 4 5
6

Similar funds

AAS
Ameritas Advisory Services Lincoln, Nebraska $4.96B AUM 27.52% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
FC
Freemont Capital Singapore $4.9B AUM 11.61% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $4.99B AUM 23.08% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $5B AUM 26.58% 1-Year Est. Return

Siren LLC's Q2 2026 Portfolio in Review

As of Q2 2026, Siren LLC held 126 positions worth $4.94B, up 37% from $3.61B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Siren LLC deployed $314M of net new capital in Q2 2026, opening 26 new positions and adding to 32 existing holdings. Its largest new stake was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Scholar Rock, an estimated $60.4M trimmed.

  • Siren LLC's largest Q2 2026 buy was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.
  • Siren LLC added most to Enliven Therapeutics in Q2 2026, an estimated $43.7M increase.
  • Siren LLC's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $60.4M.
  • Siren LLC fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $41.8M.
  • Siren LLC's ten largest holdings make up 45% of its $4.94B portfolio in Q2 2026.
  • Siren LLC opened 26 new positions and closed 9 in Q2 2026.
  • Siren LLC's portfolio value rose 37% quarter-over-quarter to $4.94B.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.